Alnylam Pharmaceuticals (ALNY)
(Delayed Data from NSDQ)
$145.61 USD
+1.20 (0.83%)
Updated Apr 22, 2024 11:55 AM ET
3-Hold of 5 3
D Value A Growth D Momentum C VGM
Income Statements
Fiscal Year end for Alnylam Pharmaceuticals, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 1,828 | 1,037 | 844 | 493 | 220 |
Cost Of Goods | 310 | 169 | 140 | 78 | 25 |
Gross Profit | 1,518 | 869 | 704 | 415 | 195 |
Selling & Adminstrative & Depr. & Amort Expenses | 1,800 | 1,654 | 1,413 | 1,243 | 1,134 |
Income After Depreciation & Amortization | -282 | -785 | -709 | -828 | -939 |
Non-Operating Income | -30 | -186 | 0 | 57 | 54 |
Interest Expense | 121 | 156 | 143 | 85 | 0 |
Pretax Income | -434 | -1,127 | -852 | -856 | -885 |
Income Taxes | 7 | 4 | 1 | 3 | 1 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -440 | -1,131 | -853 | -858 | -886 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -440 | -1,131 | -853 | -858 | -886 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -185 | -700 | -619 | -754 | -885 |
Depreciation & Amortization (Cash Flow) | 97 | 86 | 90 | 74 | 54 |
Income After Depreciation & Amortization | -282 | -785 | -709 | -828 | -939 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 124.91 | 121.69 | 118.45 | 114.99 | 109.26 |
Diluted EPS Before Non-Recurring Items | -3.52 | -9.30 | -7.20 | -7.46 | -8.11 |
Diluted Net EPS (GAAP) | -3.52 | -9.30 | -7.20 | -7.46 | -8.11 |
Fiscal Year end for Alnylam Pharmaceuticals, Inc falls in the month of December .
All items in Millions except EPS data.
3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | |
---|---|---|---|---|---|
Sales | NA | 439.72 | 750.53 | 318.75 | 319.29 |
Cost Of Goods | NA | 85.86 | 84.31 | 85.37 | 54.87 |
Gross Profit | NA | 353.86 | 666.22 | 233.38 | 264.42 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 470.26 | 452.36 | 463.22 | 414.23 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | -116.40 | 213.86 | -229.84 | -149.81 |
Non-Operating Income | NA | 10.06 | -32.23 | -14.34 | 6.40 |
Interest Expense | NA | 31.34 | 30.89 | 30.04 | 28.96 |
Pretax Income | NA | -137.69 | 150.74 | -274.21 | -172.36 |
Income Taxes | NA | 0.18 | 2.99 | 1.82 | 1.74 |
Minority Interest | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | -137.87 | 147.75 | -276.02 | -174.10 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | -137.87 | 147.75 | -276.02 | -174.10 |
Earnings Per Share Data | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 |
---|---|---|---|---|---|
Average Shares | NA | 125.61 | 131.34 | 124.66 | 124.11 |
Diluted EPS Before Non-Recurring Items | NA | -1.10 | 1.15 | -2.21 | -1.40 |
Diluted Net EPS (GAAP) | NA | -1.06 | 1.15 | -2.21 | -1.40 |